3-amino-4-halocyclopentene carboxylic acids for GABA-AT inactivation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for epilepsy and addiction, such as vigabatrin, face challenges due to low inactivation efficiency and poor blood-brain barrier permeability, leading to high daily doses and potential side effects like permanent visual damage, while existing compounds like CPP-115 and OV329 show improved efficiency but require further optimization.
Innovation Solution
Development of cyclopentene-based compounds, specifically 3-amino-4-halocyclopentene carboxylic acid derivatives, which exhibit enhanced inactivation efficiency against GABA-AT and OAT enzymes, formulated as pharmaceutical compositions to treat neurological disorders and cancers by modulating neurotransmitter and glutamine levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vigabatrin is used to treat epilepsy and addiction, then anticonvulsant activity and addiction prevention are achieved, but inactivation efficiency is low and blood-brain barrier permeability is poor, requiring high daily doses that cause permanent visual damage
Solution Approach 1:
The patent modifies the chemical structure of vigabatrin by replacing the terminal vinyl group with a cyclopentyl ring bearing amino and halogen substituents. This structural parameter change dramatically improves inactivation efficiency (several hundred-fold) while reducing the required dose, thereby eliminating the visual damage side effect associated with high-dose vigabatrin administration
Solution Approach 2:
The invention creates composite molecular structures combining the gamma-vinyl GABA pharmacophore with cyclopentyl ring systems and various halogen substituents (F, Cl, Br, I). These composite structures exhibit optimized pharmacological properties, achieving both high inactivation efficiency and improved blood-brain barrier permeability while minimizing toxic effects
2Quantity of substance
If high daily doses of vigabatrin are administered to overcome poor blood-brain barrier permeability, then adequate brain concentrations are achieved, but permanent visual damage occurs
Solution Approach 1:
The cyclopentyl ring structure with specific stereochemistry and halogen substitution patterns enhances lipophilicity and metabolic stability, improving blood-brain barrier permeability. This allows achievement of therapeutic brain concentrations at lower doses, avoiding the visual damage associated with high-dose vigabatrin
Solution Approach 2:
The patent introduces specific local modifications at the terminal position of the GABA analog - the cyclopentyl ring with amino and halogen substituents at specific positions. This localized structural optimization improves brain penetration and inactivation efficiency without compromising the essential GABA-AT inhibitory activity
3Reliability
If mechanism-based inactivators are used to increase brain concentrations of GABA, then anticonvulsant effect is achieved, but off-target effects may occur due to reactive species formation
Solution Approach 1:
The cyclopentene derivative acts as a mechanism-based inactivator that forms a covalent intermediate with the PLP cofactor in the GABA-AT active site. This controlled intermediary reaction selectively inactivates the target enzyme without generating free radical species that could cause off-target damage, achieving therapeutic effect with improved safety profile
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cyclopentene compounds demonstrate significantly improved inactivation efficiency and reduced side effects, offering a more effective treatment for epilepsy, addiction, and cancer by effectively modulating enzyme activity with lower doses and minimal toxicity.
Implementation Method 1
mechanism-based inactivators (MBIs) of GABA-AT are attractive because of their unique inactivation mechanisms
Implementation Method 2
it irreversibly inhibits GABA-AT by covalent modification through two different mechanisms, a Michael addition pathway (70%) and an enamine pathway (30%)
Implementation Method 3
pharmacological inhibition of certain ATs (e.g., γ-aminobutyric acid AT and ornithine AT) is a therapeutic strategy
Data Source
AI summary
Disclosed are cyclopentene compounds for use as inhibitors of aminotransferases such as gamma-aminobutyric acid (GABA) aminotransferase (AT) and/or ornithine aminotransferase (OAT). The disclosed cyclopentene compounds include 3-amino-4-halocyclopente carboxylic acid compounds which may be formulated in pharmaceutical composition for treating diseases and disorders associated with GABA-AT and/or OAT activity, including epilepsy, addiction, hepatocellular carcinoma (HCC), and non-small cell lung cancer (NSCLC).